Further references to Progressive Multifocal Leukoencephalopathy
Source: Diseases Database
Source: Diseases Database
Source: Office of Rare Diseases
Progressive Multifocal Leukoencephalopathy is listed as a "rare disease" by the Office of
Rare Diseases (ORD) of the National Institutes of Health
(NIH). This means that Progressive Multifocal Leukoencephalopathy, or a subtype of Progressive Multifocal Leukoencephalopathy,
affects less than 200,000 people in the US population.
Source - National Institutes of Health (NIH)
Source: Other References
Portegies, P.
Response to Cytarabine in Progressive
Multifocal Leukoencephalopathy in AIDS. The Lancet, 337; 680-681 (March
16, 1991).
Hall, CD, et al.
Failure of Cytosine Arabinoside Therapy of
HIV-1 Associated Progressive Multifocal Leukoencephalopathy. New England
Journal of Medicine, 338; 1345-1351 (1998).
Koralnik, I, et al.
JC Virus DNA Load in Patients With and
Without PML. Neurology; 52: 353-358 (1999).
Berger, JR, and Major, EO
The Pathogenesis and Clinical
Course of Progressive Multifocal Leukoencephalopathy. Seminars in
Neurology, Berger, JR, and Pascuzzi, RM, eds, 19 (2); 193-200 (1999).
Yiannoutsas, C, et al.
Relation of JC Virus DNA in the
Cerebralspinal Fluid to Survival in AIDS Patients With Biopsy Proven
Progressive Multifocal Leukoencephalopathy. Annals of Neurology, 45;
816-845 (1999).
Power, C, et al.
Non-AIDS and AIDS Related Progressive
Multifocal Leukoencephalopathy: Association With Distinct p53
Polymorphisms. Neurology, 54; 743-746 (2000).
(Source: excerpt from NINDS Progressive Multifocal Leukoencephalopathy Information Page: NINDS)
